TransMedics Group (TMDX) Q4 2024 earnings summary

Executive summary

• Achieved record revenue growth in Q4 and full year 2024, with Q4 revenue at $121.6M (up 50% YoY) and full year revenue at $441.5M (up 83%), driven by increased OCS adoption and logistics expansion.

• Net income was $6.9M in Q4 and $35.5M for 2024, reversing a $25M loss in 2023; diluted EPS was $0.19 in Q4 and $1.01 for the year.

• Completed 3,715 U.S. OCS cases in 2024, a 58% increase from 2023; OCS market share rose to 20.9% from 13.8%.

• Independent investigation and review found no evidence of fraud or misconduct following short report allegations.

• Continued investment in clinical programs, R&D, and logistics infrastructure to support future scalability and innovation.

Financial highlights

• Q4 2024 gross margin was 59.2% (up from 59.0% in Q4 2023); full year gross margin was 59.4%, down from 63.8% in 2023 due to higher service revenue mix.

• Q4 operating profit was $8.6M (7.1% margin); full year operating profit was $37.5M.

• Operating expenses for 2024 were $224.6M, up from $182.8M in 2023, driven by R&D and organizational growth.

• Ended 2024 with $336.7M in cash after investing $112M in aircraft purchases.

• Convertible senior notes and long-term debt totaled $509.3M at year-end.

Outlook and guidance

• 2025 revenue guidance set at $530M–$552M, representing 20–25% growth over 2024.

• Growth expected to be led by liver, with heart and lung clinical programs contributing 2–5% of growth in the back half of 2025.

• Modest improvements anticipated in gross and operating margins, with continued investment in R&D and infrastructure.

• Variability in quarterly results expected due to seasonality and timing of clinical program launches.